Tue. 7 May 2024, 4:50pm ET
Benzinga
Earnings, Earnings Beats, News
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.70) by 2.86 percent. This is a 15 percent increase over losses of $(0.80) per share from the same period last year.